Marteau P, Ballet F, Chazouillères O, Chrétien Y, Rey C, Petit D, Poupon R
Equipe de Physiologie et de Pharmacologie Hépatique, INSERM U.181, Hôpital Saint-Antoine, Paris, France.
Hepatology. 1989 Jun;9(6):820-3. doi: 10.1002/hep.1840090605.
We studied the effects of a series of vasodilators on intrahepatic vascular resistance of isolated perfused cirrhotic rat livers in basal conditions and during norepinephrine-induced vasoconstriction. Cirrhosis was induced by repeated intraperitoneal injections of carbon tetrachloride. The vasodilators were a nonselective beta-adrenergic antagonist (propranolol), an alpha 1-adrenergic antagonist (prazosin), a nonselective beta-adrenergic agonist (isoproterenol), an alpha 2-agonist (clonidine), nitrovasodilators (nitroglycerin and nitroprusside), calcium channel blockers (verapamil, diltiazem, nifedipine), papaverine, diazoxide and pentoxifylline. In basal conditions, isoproterenol, nitroglycerin, papaverine, pentoxifylline and nitroprusside demonstrated significant vasodilatory activity. However, the response was weak and isoproterenol was the only drug active in the therapeutic range of concentrations. Propranolol, prazosin, verapamil, diltiazem, nifedipine and diazoxide were ineffective. Prazosin, papaverine and pentoxifylline reduced norepinephrine-induced vasoconstriction, whereas isoproterenol, clonidine and propranolol were ineffective. We conclude that several vasodilators can reduce resistance in the cirrhotic rat liver, but their potency is low and few are effective at therapeutic concentrations. Furthermore, their activity may be blunted when resistance is increased by norepinephrine.
我们研究了一系列血管扩张剂对基础状态下以及去甲肾上腺素诱导血管收缩期间分离灌注的肝硬化大鼠肝脏肝内血管阻力的影响。通过反复腹腔注射四氯化碳诱导肝硬化。血管扩张剂包括非选择性β-肾上腺素能拮抗剂(普萘洛尔)、α1-肾上腺素能拮抗剂(哌唑嗪)、非选择性β-肾上腺素能激动剂(异丙肾上腺素)、α2-激动剂(可乐定)、硝基血管扩张剂(硝酸甘油和硝普钠)、钙通道阻滞剂(维拉帕米、地尔硫䓬、硝苯地平)、罂粟碱、二氮嗪和己酮可可碱。在基础状态下,异丙肾上腺素、硝酸甘油、罂粟碱、己酮可可碱和硝普钠表现出显著的血管舒张活性。然而,反应较弱,异丙肾上腺素是唯一在治疗浓度范围内有活性的药物。普萘洛尔、哌唑嗪、维拉帕米、地尔硫䓬、硝苯地平和二氮嗪无效。哌唑嗪、罂粟碱和己酮可可碱可减轻去甲肾上腺素诱导的血管收缩,而异丙肾上腺素、可乐定和普萘洛尔无效。我们得出结论,几种血管扩张剂可降低肝硬化大鼠肝脏的阻力,但其效力较低,且在治疗浓度下有效的药物很少。此外,当去甲肾上腺素增加阻力时,它们的活性可能会减弱。